Bioxytran, Inc.
BIXT
$0.03
$0.000.00%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 931.16% | 33.33% | 68.02% | -79.57% | -77.98% |
| Depreciation & Amortization | 10.53% | 0.00% | 180.00% | 66.67% | -5.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 274.31% | 24.23% | 43.86% | -62.91% | -33.83% |
| Operating Income | -274.31% | -24.23% | -43.86% | 62.91% | 33.83% |
| Income Before Tax | -52.85% | 30.57% | 27.96% | 105.35% | -135.90% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.85% | 30.57% | 27.96% | 105.35% | -135.90% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.85% | 30.57% | 27.96% | 105.35% | -141.50% |
| EBIT | -274.31% | -24.23% | -43.86% | 62.91% | 33.83% |
| EBITDA | -275.29% | -24.37% | -43.27% | 63.22% | 33.89% |
| EPS Basic | -21.05% | 35.80% | -3.23% | 110.81% | -347.06% |
| Normalized Basic EPS | -21.05% | 39.71% | -5.26% | 108.70% | -216.67% |
| EPS Diluted | -21.05% | 35.80% | -3.23% | 110.81% | -347.06% |
| Normalized Diluted EPS | -21.05% | 39.71% | -5.26% | 108.70% | -216.67% |
| Average Basic Shares Outstanding | 26.39% | 8.19% | -29.59% | -49.70% | -45.65% |
| Average Diluted Shares Outstanding | 26.39% | 8.19% | -29.59% | -49.70% | -45.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |